6-Methylene-13-propyl-4,8-di(p-toluenesulfonyl)-4,8,15-triazabicyclo[9.3.1]pentadeca-1(15),11,13-triene Hydrochloride

ID: ALA4758659

Chembl Id: CHEMBL4758659

PubChem CID: 162658351

Max Phase: Preclinical

Molecular Formula: C30H38ClN3O4S2

Molecular Weight: 567.78

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  C=C1CN(S(=O)(=O)c2ccc(C)cc2)CCc2cc(CCC)cc(n2)CCN(S(=O)(=O)c2ccc(C)cc2)C1.Cl

Standard InChI:  InChI=1S/C30H37N3O4S2.ClH/c1-5-6-26-19-27-15-17-32(38(34,35)29-11-7-23(2)8-12-29)21-25(4)22-33(18-16-28(20-26)31-27)39(36,37)30-13-9-24(3)10-14-30;/h7-14,19-20H,4-6,15-18,21-22H2,1-3H3;1H

Standard InChI Key:  SVHQKFHNAGYFFO-UHFFFAOYSA-N

Associated Targets(Human)

CD4 Tclin T-cell surface antigen CD4 (114 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MT4 (17854 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Human immunodeficiency virus 1 (70413 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 567.78Molecular Weight (Monoisotopic): 567.2225AlogP: 4.69#Rotatable Bonds: 6
Polar Surface Area: 87.65Molecular Species: NEUTRALHBA: 5HBD: 0
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 0#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 4.60CX LogP: 5.59CX LogD: 5.59
Aromatic Rings: 3Heavy Atoms: 39QED Weighted: 0.40Np Likeness Score: -0.49

References

1. Lumangtad LA,Claeys E,Hamal S,Intasiri A,Basrai C,Yen-Pon E,Beenfeldt D,Vermeire K,Bell TW.  (2020)  Syntheses and anti-HIV and human cluster of differentiation 4 (CD4) down-modulating potencies of pyridine-fused cyclotriazadisulfonamide (CADA) compounds.,  28  (24): [PMID:33181479] [10.1016/j.bmc.2020.115816]

Source